<DOC>
	<DOCNO>NCT01740336</DOCNO>
	<brief_summary>This multicenter , randomize , single-blind , placebo-controlled , two arm study evaluate efficacy safety paclitaxel GDC-0941 versus paclitaxel placebo patient locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>A Study Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female adult patient Histologically cytologically confirm adenocarcinoma breast , measurable nonmeasurable locally recurrent metastatic disease Human epidermal growth factor receptor 2 ( HER2 ) negative HR ( estrogen receptor and/or progesterone receptor ) positive disease define local guideline Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic end organ function Women childbearing potential must agree remain abstinent use two adequate method contraception , include least one method failure rate &lt; 1 % per year , treatment period least 30 day last dose study treatment 6 month discontinuation paclitaxel , whichever long Prior noncapecitabine chemotherapy locally recurrent metastatic disease Prior treatment PI3K inhibitor advance metastatic breast cancer History intolerance taxanecontaining therapy History clinically significant cardiac pulmonary dysfunction History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease Active autoimmune disease active inflammatory disease Immunocompromised status Need current chronic corticosteroid therapy Pregnancy , lactation , breastfeed Current severe , uncontrolled systemic disease Known untreated active central nervous system ( CNS ) metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>